期刊
CNS NEUROSCIENCE & THERAPEUTICS
卷 17, 期 1, 页码 58-65出版社
WILEY
DOI: 10.1111/j.1755-5949.2010.00211.x
关键词
Affective disorders; Cognitive impairment; Drug discovery; Movement disorders; Parkinson's disease; Schizophrenia; 5-HT1A receptors
P>5-HT1A receptors have long been implicated in the pathogenesis and treatment of anxiety and depressive disorders. Recently, several lines of studies have revealed new insights into the therapeutic role of 5-HT1A receptors in treating schizophrenia and Parkinson's disease. Specifically, 5-HT1A receptors seem to be a promising target for alleviating antipsychotic-induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia. In the treatment of patients with Parkinson's disease, 5-HT1A agonists are expected to improve not only affective symptoms (e.g., anxiety and depression), but also the core parkinsonian symptoms as well as antiparkinsonian agents-induced side effects (e.g., L-DOPA-induced dyskinesia). Here, the therapeutic mechanisms mediated by 5-HT1A receptors in schizophrenia and Parkinson's disease are reviewed. This evidence should encourage discovery of new 5-HT1A ligands, which can resolve the unmet clinical needs in the current therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据